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A B S T R A C T
Gastric bypass surgery is indicated for several clinical reasons including benign and malignant upper gas-
trointestinal tract pathologies. Any gastric resection or bypass procedure interferes with gastric emptying
and the aim of reconstruction is to minimize the disturbance to the upper gastrointestinal physiology.
Gastric bypass procedures induce early satiety, with or without concomitant impaired absorption of nu-
trients, and offer the best solution for morbid obesity. The long-term health beneﬁts of gastric bypass
surgery for morbid obesity must be found to outweigh the operative risks and side-effects of gastric bypass
and thus patient selection is fundamental. The aim of the study was to review the indications, compli-
cations, sequelae and outcome of gastric bypass procedures.
© 2016 The Author. Published by Elsevier Ltd on behalf of Surgical Associates Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
The history of gastric bypass surgery began in 1880 when the
Polish surgeon Ludwik Rydygier performed a gastroenterostomy for
peptic ulcer disease [1]. In 1885, the Austrian surgeon Theodor
Billroth (Fig. 1) performed a ﬁrst-stage gastrojejunostomy to alle-
viate the symptoms of an obstructing large pyloric tumour followed
by a second-stage resection of the tumour with restoration of gas-
troduodenal continuity [1,2]. Mostmodern forms of gastrectomywith
gastrojejunal anastomosis (Billroth II) are modelled on this oper-
ation and described for the treatment of peptic ulcer disease in 1911
[2–4]. With the success of antral Helicobacter pylori eradication triple
therapy for peptic ulcer disease which includes antibiotics and a re-
versible chemical vagotomy with H2 receptor antagonist or proton
pump inhibitor, surgery is now indicated only for the emergency
complications of perforation, severe vomiting from pyloric steno-
sis and haemorrhage [5]. It was also well recognized that Billroth
II (partial) gastrectomy is associated with weight loss and several
variations of this procedure have been used effectively in the sur-
gical treatment of morbid obesity with beneﬁt lasting for up to 10
years [4,6–11]. The restriction of volume of ingested food togeth-
er with altered absorption of nutrients, especially fat contributes
to achieving the weight loss and the malabsorptive procedures alter
the digestive process in different ways [8–11]. The aim of this review
was to evaluate the common gastric bypass procedures with regard
to their indications, sequelae and outcome.
2. Gastrojejunostomy
By diverting gastric acid away from the duodenum, anastomo-
sis of the stomach to a loop of jejunum was once used to treat
duodenal ulcer but carried a high recurrence (50%) rate [12]. Gas-
trojejunostomy was then used as a drainage procedure following
truncal vagotomy for peptic ulcer disease but has fallen into disuse
since the advent of effective medical treatment to suppress gastric
acid output and antral helicobacter pylori invasion [13,14]. Lapa-
roscopic gastrojejunostomy (LGJ) has beenproposed as the technique
preferred over open gastrojejunostomy for relieving gastric outlet
obstruction (GOO) due to malignant and benign disease with im-
proved outcome and an acceptable complication rate [15].
Gastrojejunostomywould also bypass congenital pre-ampullary du-
odenal obstruction from a duodenal web/atresia/stenosis and an
annular pancreas, with no or minimal early or long term compli-
cations includingmalnutrition [16]. Although resection of a primary
gastric tumour provides better palliation than bypass surgery pro-
vided the patient’s general health will allow this, patients with
unresectable distal gastric tumoursmaybeneﬁt fromahigh antecolic
gastrojejunostomy [17–19]. The control of the rate of delivery of the
gastric contents to the small intestine that allows adequate mixing
with bile and pancreatic juices and avoids overwhelming the di-
gestive and absorptive capacity of the small intestine requires an
intact and innervated pylorus. The importance of attempting to pre-
serve normal gastric emptying in gastric bypass procedureswithout
compromising oncological results is seen with the more physio-
logical post-operative digestive function of the pylorus – preserving
partial pancreaticoduodenectomy for pancreatic head cancer than
with the partial stomach resection of the classical Kausch–Whipple
procedure [20]. The Whipple’s procedure is also occasionally indi-
cated in cases of duodenal or pancreatic head trauma. Following a
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retroperitoneal duodenal injury, options for duodenal repair may
include apyloric exclusioneffected throughagastrostomy. Thepyloric
ring is closedwith a continuous suture or staplingwhichbreaksdown
after several weeks. The procedure is combined with a gastrojeju-
nostomy and the addition of octreotide and intravenous acid
suppression may improve duodenal healing and decrease stomach
ulceration. Roux-en-Y loop (Roux-en-Y duodenojejunostomy) drain-
age of the defect from signiﬁcant tissue loss in the second part of
the duodenum is the procedure of choice in the stable patient [21].
Both the duodenum and the bile duct are triply bypassed with a
gastroenterostomy, and a retrocolic Roux-en-Yhepatico-jejunostomy
for a duodenal obstructive, locally-advanced pancreatic head car-
cinoma [22]. However a prophylactic gastrojejunostomymay suﬃce
for an obstructive unresectable periampullary carcinoma [23].
2.1. Complications
Early technical complications from a gastrojejunostomy would
include: (a) haemorrhage which is usually from the gastric side of
the anastomosis and usually only starts when the clamps are re-
leased, bywhich time the lumen is not visible. It occasionally requires
exploration; (b) leakagemay occur as a result of tension on the anas-
tomosis. Diﬃculty in bringing the stomach and jejunum together
without tension may require opening the gastrocolic omentum and
performing a retrocolic posterior gastroenterostomy. Otherwise, there
is little advantage over the simple antecolic gastroenterostomy
[24,25]; (c) an internal hernia if themesenteric defects are not closed;
(d) sepsis, either as a wound infection or an intraabdominal abscess;
(e) early obstruction follows oedema around the stoma or kinking,
or, later due to progression of malignancy especially if done for pal-
liation. Late complications include stomal ulceration which can be
prevented by proton pump inhibition and pancreatitis due to af-
ferent loop obstruction [6,24].
3. Billroth II gastrectomy
The Billroth II gastrectomy is often indicated for refractory peptic
ulcer disease and gastric adenocarcinoma [14,26,27]. Except in the
aged, most surgeons now opt for a partial gastrectomy to treat a
resistant peptic ulcer after excluding acid hypersecretion fromapan-
creatic islet cell gastrinoma [14,26]. Following resection of the distal
stomach, reconstruction can be performed by either fashioning a
new lesser curve and creating an end-to-end gastroduodenal anas-
tomosis (Billroth I gastrectomy) described in 1881, or, by an end-
to-side anastomosis of the gastric remnant to a loop of jejunum,
with closure of the duodenal stump (Billroth II or Polya gastrec-
tomy) (Fig. 1) [2–4]. The Polya gastrectomy with retrocolic end-to-
side gastrojejunostomy has become a commonly performed
modiﬁcation of the Billroth II procedure [2]. Franz von Hofmeister
described a partial gastrectomy with a retrocolic gastrojejunos-
tomy involving the greater curvature [2,28]. Reconstruction following
partial gastrectomymay be simple or diﬃcult depending partly on
the build of the patient and partly on the extent and nature of the
disease process. Thus Billroth II gastrectomy is usually used for an
emergency perforated large duodenal ulcer not suitable for simple
omental patch closure and when a duodenal anastomosis (Billroth
1) cannot easily bemade [29]. A Billroth I gastrectomy is not a bypass
procedure and is suitable for a resistant benign gastric ulcer after
excludingmalignancy [14,27]. The Billroth II is associatedwith prob-
lems of bile reﬂux into the gastric remnant and oesophagus, and a
higher risk of stomal ulceration. Thus, approximately two-thirds of
stomach should be resected to avoid repeated antral exposure to
bile [6,14]. For the theoretical beneﬁts of delaying gastric emptying
and preventing reﬂux of duodenal contents into the stomach, a
Hofmeister ‘valve’ canoftenbe fashionedby reducing the stoma length
to around 5 cm through closing part of the opening in the gastric
stump and the rest being used for the actual anastomosis [28].
3.1. Complications
Billroth II gastrectomy was favoured for many years for its rel-
atively low peptic ulcer recurrence rate (less than 5%) [2,4,6].
However, it has a highmortality and complication rate [6,14]. Leakage
may occur from either the duodenal stump or from the anastomo-
sis. Leakage from the duodenal stump is usually due to afferent loop
obstruction. This risk is reduced by the formation of a Roux-en-Y
reconstruction. If there is controlled leak without sepsis or gener-
alized peritonitis conservative treatment is indicated with parenteral
nutrition. Otherwise exploration is required to drain any sepsis and
to establish drainage of the afferent loop. A useful technique for the
latter is to insert a T tube into the duodenum and, therefore, es-
tablish a controlled ﬁstula, and to decompress the afferent loo
obstruction [6,30,31]. It is unlikely that direct suture of a leak will
be feasible. Treatment of a gastrojejunal leak is problematic. More
commonly the leak is delayed, occurring 7–14 days postopera-
tively. If there are clinical features to indicate that this is limited
and localized, then conservative treatment with nutritional support,
gastrointestinal decompression and antibiotics is indicated .Other-
wise, reoperation is required.
3.2. Side effects and post-prandial sequelae
3.2.1. Early satiety
Early satiety arises from the loss of reservoir function of the
stomach and it is important to obtain good early dietary advice and
limit meal size. The excision of 80% of the stomach leads to reduced
gastric volume resulting in early satiety and hence weight loss.
Gastric bypass surgery not only reduces the gut’s capacity for food
but also dramatically lowers ghrelin levels compared to both lean
controls and those that lost weight through dieting alone [32,33].
Ghrelin, the “hunger hormone”, is a peptide hormone produced by
ghrelinergic cells in the gastrointestinal tract which functions as a
neuropeptide in the central nervous system. Besides regulating ap-
petite, ghrelin also plays a signiﬁcant role in regulating the
distribution and rate of use of energy [34]. It prepares the body for
food intake by acting on hypothalamic brain cells to increase hunger,
gastric acid secretion and gastrointestinal motility [35,36]. Ghrelin
is secreted when the stomach is empty, but secretion stops when
the stomach is stretched. Bariatric surgeries involving excision of
the fundus as in vertical sleeve gastrectomy reduce plasma ghrelin
levels by about 60% in the long term [37]. However, studies are con-
ﬂicting as to whether or not ghrelin levels return to nearly normal
Fig. 1. Diagram of Billroth II gastrectomy.
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with gastric bypass patients in the long term after weight loss has
stabilized [38].
3.3. Post-prandial sequelae
There is a distressing array of new gastrointestinal symptoms
(‘post gastrectomy syndrome’) resulting from the loss of reservoir
function, denervation, disruption of the pyloric mechanism and the
type of reconstruction. Post gastrectomy syndromes include
metabolic/nutritional alterations, dumping syndrome, bile reﬂux gas-
tritis, gastroparesis, afferent/efferent limb syndromes, the Roux
syndrome and postvagotomy diarrhoea. About 25% of patients will
develop post gastrectomy syndrome but only 1–4% develop severe
debilitating symptoms. It is made worse by bad technique. Too ex-
tensive a resection predisposes to a high incidence of postprandial
symptoms including early dumping that severely limits calorie intake
[14,39].
3.3.1. Early dumping
Post gastrectomy complications may occur as vasomotor
‘dumping’ due to rapid gastric evacuation from loss of pyloric reg-
ulation and receptive relaxation resulting in a hypertonic load to
the small intestine triggering autonomic reﬂexes and release of va-
soactive peptides. Fluid shifts can cause hypotension triggering
autonomic catecholamine surge. Multiple gut hormones impli-
cated include serotonin, vasoactive intestinal peptide (VIP),
cholecystokinin (CCK), neurotensin, peptide YY, enteroglucagon etc.
The rapid ﬁlling of proximal small intestine with hypertonic food
also leads to rapid movement of ﬂuid into the gut from extracel-
lular space resulting in diarrhoea. The characteristic symptoms of
early dumping are epigastric fullness, sweating, faintness and pal-
pitations 30 min after eating and may last for an hour. These can
lead to food avoidance with reduced quality of life and malnutri-
tion. It is more troublesome following subtotal gastrectomy or where
pylorus is destroyed or bypassed. Dumping symptoms are quite
common in the ﬁrst weeks or months but improve over the months
from small bowel adaptation or unconscious modiﬁcation of diet
[40,41]. 1–2% have debilitating symptoms but because of genuine
reassurance to the patient, dietary advice to eat small meals, re-
strict carbohydrate intake and avoid too much ﬂuid less than 1%
requires surgical intervention. In many patients there is develop-
ment of malnutrition, manifested as anaemia and weight; loss in
the ﬁrst fewmonths after operation to a new level which then stays
steady [14,41].
As many of the postgastrectomy problems are due to by-pass of
the duodenum and loss of gastric capacity, dumping may be di-
minished by conversion to a Billroth I anastomosis, a Roux-en-Y
reconstruction or by interposing a 10–15 cm segment of proximal
jejunum aimed at slowing down gastric emptying [14,27]. Unfor-
tunately, the use of gastric pouches or jejunal interpositions has not
signiﬁcantly improved on the results of more standard reconstruc-
tions. A particular hazard of jejunal interposition is an increased risk
of bile and alkaline reﬂux with consequent peptic ulceration at the
new gastrojejunal junction. The defect of normal peristalsis in the
long jejunal limb may also result in voluntary and involuntary re-
gurgitation. And so this operation should only be used in those with
severe degree of dumping or small stomach syndrome and a proton
pump inhibitor (PPI) given. The beneﬁcial effect of the Roux-en-Y
is thought to be due to transection of the neural plexuses that ef-
fectively slow gastric emptying in the long jejunal limb [41].
3.3.2. Reactive hypoglycaemic attacks
Complex neurohumoral response produces unpleasant gastro-
intestinal and cardiovascular symptoms. Rapid carbohydrate
absorption stimulates excessive or asynchronous insulin secretion
causing a rebound hypoglycaemia, blackouts, and seizures 2–3 h fol-
lowing a meal (late dumping). Dietetic input is crucial and involves
reducing amount of carbohydrate inmainmeals with regular glucose
in-between (glucose tablets) [6,39,42].
3.3.3. Diarrhoea
Diarrhoea is caused by truncal or inevitable vagotomy, early
dumping, and bacterial overgrowth [39,41,42]. The combination of
loss of gastric acid and formation of blind loops results in accumu-
lation of aerobic and anaerobic organisms normally found in colon.
Faecal bacteria release toxins that destroy brush borders vital to di-
gestion and consume B vitamins. They deconjugate bile acids
essential for normal fat absorption in the proximal small intes-
tine. The increased faecal fats result in steatorrhoea and weight loss.
Investigation involves 14C glycocholate breath test and treatment in-
cludes the antibiotics (metronidazole/neomycin) and probiotics (fresh
unpasteurized yoghurt) to inhibit recolonization with and after an-
tibiotics. Relative pancreatic insuﬃciency may also result in
steatorrhoea but once bacterial overgrowth is excluded, it can be
treated with pancreatic enzyme supplementation (Creon). Post va-
gotomy diarrhoea is due to vagal denervation leading to intestinal
dysmotility, rapid gastric emptying of liquids, hypoacidity, malab-
sorption of bile acids and bacterial overgrowth in the proximal bowel.
Severe form of post vagotomy diarrhoea may have 10–20 epi-
sodes per day, often explosive with no temporal relationship with
food and occurring at all times even during sleep. It is associated
with malnutrition, weight loss, and weakness [6,42]. 1% of post va-
gotomy diarrhoea are refractory to medical treatment (dietary
modiﬁcations, bile chelator (cholestyramine), oral neomycin,
antidiarrhoeal agents) and severe enough for surgical interven-
tion. The antiperistaltic jejunal interposition 75–100 cm from the
ligament of Treitz or the Cuschieri reversed distal ileal onlay graft
gives relief for the majority [43],
3.3.4. Bilious vomiting
Bile reﬂux gastritis is more common after Billroth II gastrec-
tomy and less with Roux-en-Y procedure. It commonly occurs after
gastric reconstructionwithdebilitating symptoms in1–2%. The symp-
toms of alkaline bile reﬂux are epigastric discomfort, heartburn, and
vomiting. Persistent reﬂux can lead to stricturing and dysphagia
[43,44]. It would be diagnosed by upper gastrointestinal endosco-
py and Tech 99MHIDA scanning. Gastric emptying studywould rule
out gastroparesis [44,45]. Medical management with PPIs and H2
blockers is rarely helpful thus requiring revisional surgery. Biliary
diversion is usedmost often for severe bilious vomiting or if symp-
toms are unremitting as treatment options are limited and only often
successful. A simple version is jejuno-jejunostomy between the af-
ferent and efferent limbs of a gastrojejunostomy (Uddin loop)where
the former is quite long. An alternative common variety is a sub-
total (80%) gastrectomy with Roux-en-Y reconstruction with the
efferent loop some 40–50 cm distal to the stoma or lengthening of
Roux loop which gives 80% relief [46]. Again proton pump inhibi-
tion would reduce the risk of gastrojejunal ulceration [14].
Gastro-oesophageal reﬂux disease (GORD) is more prevalent as
body mass index (BMI) increases. There is reduced long-term ef-
fectiveness of anti-reﬂux (Nissen fundoplication) procedure in obese
patients (BMI >30). Laparoscopic Roux-en-Y gastric bypass is themost
effective and recommended option as it treats GORD, reduces weight,
and improves comorbidities [47]. Likewise, bile reﬂux following
gastric bypass for morbid obesity will beneﬁt from the very effec-
tive and much simpler anti-reﬂux (laparoscopic Nissen
fundoplication) procedure than revision surgery [48].
Gastroparesis is delayed gastric emptying in the absence of me-
chanical obstruction. It is the most common (50%) of the post
gastrectomy syndromes especially with associated truncal va-
gotomy, and, generally inversely proportional to the extent of gastric
resection [49,50]. The patient is unable to tolerate diet 7–14 days
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after surgery but the vast majority improves with time or with
prokinetic agents. Other causes i.e. metabolic (electrolyte, endo-
crine, medications), mechanical (stoma oedema, small leaks,
adhesions, kinking, haematoma, intussusception, stricture) should
be ruled out. Sometimes surgery is required with the original op-
eration dictating the corrective procedure, i.e. further resection
following a partial resection. Most advocate R-Y reconstruction and
completion vagotomy [51] .
3.3.5. Afferent/efferent loop syndromes
Afferent loop syndrome is a mechanical problemwith partial ob-
struction of the afferent limb from kinking, angulation, stenosis or
adhesions. The afferent limb being almost always 30–40 cm or longer
is a predisposing factor and always occurs with a Billroth II bypass.
Treatment is always surgical. It entails either revision of Billroth II,
conversion of Billroth II to Billroth I, conversion of a Billroth II to
R-Y with a long Roux limb and complete vagotomy to prevent mar-
ginal ulcer or fashioning an entero-enterostomy below the stoma
if adhesions are present [30]. The Chronic type is more common.
The severe post prandial pain, bile and pancreatic secretions build
up in the afferent limb until the intraluminal pressure overcomes
the obstruction resulting in projectile bilious vomiting with im-
mediate relief of pain. The efferent loop syndrome is less common
and diﬃcult to distinguish from afferent loop syndrome or bile reﬂux
gastritis. It is usually due to adhesions or an internal hernia of the
limb behind the gastrojejunal anastomosis and treatment is always
surgical.
3.3.6. The Roux syndrome
The Roux syndrome is a complex of symptoms including post
prandial epigastric fullness, nausea, intermittent vomiting and often
weight loss. It is thought to be the result of an atonic roux limb that
impedes gastric emptying. Studies have demonstrated that it is a
result of loss of the duodenal pacesetter potentials which are fastest
in the duodenum and spread distally to the terminal ileum. The fre-
quency is decreased when the jejunum is resected and ectopic
pacemakers spread retrogradely to the stomach. It is thus com-
moner with a large gastric remnant and after truncal vagotomy.
Treatment is with a trial of prokinetic agents or aggressive gastric
resection with R-Y reconstruction [52].
4. Nutritional problems
Malnutrition following gastric bypass is usually due to failure
to ingest suﬃcient calories especially in total gastrectomy pa-
tients. Malabsorption is a rare cause of malnutrition in non-
bariatric gastric bypass surgery. Carbohydrate absorption is usually
satisfactory but protein and particularly fat absorption is reduced
resulting in weight loss. Close dietetic follow-up should ensue after
bacterial overgrowth, early satiety, dumping, and relative pancre-
atic insuﬃciency have been excluded.
4.1. Vitamin B12 deﬁciency and macrocytic anaemia
As vitamin B12 is bound to intrinsic factor secreted by the pari-
etal cells in the body and fundus of the stomach and absorbed in
the terminal ileum, there is virtually no absorption of B12 post gas-
trectomy. B12 deﬁciency is always seen following total gastrectomy
and in about 50% of those patients who undergo partial gastrec-
tomy. Methyl-methionine testing is more accurate than serum B12
in the presence of proton pump inhibitor use. Vitamin B12 deﬁcien-
cy usually takes some years to develop because of the large body
stores of the vitamin [6,42]. All gastrectomy patients require
3-monthly hydroxocobalamin injections. The stagnant loop syn-
drome which arises as a consequence of anatomical abnormalities
of the small intestine including blind loops results in bacteria over-
growth in the jejunum. The effects are complex, but malabsorption
of fat, vitamin B12 and other B vitamins is usually present. A course
of broad-spectrum antibiotics will usually temporarily restore
vitamin B12 absorption to normal, but complete cure may require
revisional surgery [6,14,53]. Patients should be supplemented with
vitamin B during and after treatment. Vitamin D malabsorption
results in osteomalacia especially in post-menopausal women. Thus
all patients >70 years would receive calcium supplements and
undergo 5-yearly assessments for metabolic bone disease.
4.2. Iron deﬁciency anaemia
Iron deﬁciency anaemia is present in 40–50% of patients fol-
lowing partial gastrectomy [42]. In addition to impaired dietary
intake, achlorhydria is associated with impaired absorption of iron
in the duodenum and jejunum as reduced ferrous (Fe2) rather than
food ferric (Fe3) ion is absorbable. Iron malabsorption is not nor-
mally an issue unless vegetarian, as small intestine takes over
absorption. Iron and vitamin C supplements should be considered
for the ﬁrst post-operative year [42,53].
5. Gastric cancer
The risk of Gastric malignancy in the remnant stomach is in-
creased about 4-fold. The exact mechanism is unclear, but
achlorhydria, atrophic gastritis, persistent bile reﬂux, denervation
of the gastric mucosa and bacterial invasion of the gastric stump
have been regarded as possible aetiologies [54,55]. The gastric
mucosa of the patients who underwent gastric surgery for malig-
nancy tends to develop recurrent cancer, less than 10 years after
surgery at the anastomosis site and new cancers at the non-
anastomosis site. Those patients with initially benign disease may
develop cancer but more than 10 years after at the anastomosis site
[56]. By attenuating the chronic gastritis–metaplasia–dysplasia–
carcinoma sequence, there is a role for H. pylori eradication therapy
in preventing anastomotic recurrence or a new primary [27,56].
6. Bariatric surgical procedures that involve gastric bypass
Morbid obesity deﬁned as a body mass twice ‘ideal’ (Body mass
index >39 kg/m2) has a high health risk and excess mortality [7].
The National Institute of health and Clinical Evaluation (NICE) guide-
lines (2006) recommend bariatric surgery as a treatment option for
people with morbid obesity (BMI >40 kg/m2) or who have lower BMI
(35 kg/m2) plus other signiﬁcant disease such as type 2 diabetes mel-
litus and hypertension that could improve if they lost weight. Because
of the risks, surgery is only offered when all appropriate non-
surgical measures are unsuccessful [8]. Several variations of Billroth
II gastrectomy as a form of biliopancreatic bypass have been de-
scribed and not surprisingly the more complex operations are
associated with a higher incidence of morbidity [9]. The most com-
monly performed procedure is the Roux-en-Y gastric bypass (RYGB)
[10]. Biliopancreatic diversion (BPD), with or without duodenal
switch (BPD-DS), is less commonly performed but is often consid-
ered in extremely obese individuals [11]. All procedures can be
performed laparoscopically with a lower rate of complications such
as wound infection and incisional hernias [57,58].
6.1. Roux-en-Y gastric bypass (RYGB)
RYGB is a combination of both restriction and malabsorption. The
creation of a small stomach pouch leads to early satiety combined
with the bypassing of the stomach, duodenum and up to 200 cm
of jejunum leading to malabsorption. Release of distal gut hor-
mones and changes in taste also have a role in the mechanism of
action. Technically, the stomach is divided (stapled) into an upper
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gastric pouch, which is 15–30 ml in volume, and a lower gastric
remnant. The gastric pouch is anastomosed to the jejunum after it
has been divided some 30–75 cm distal to the ligament of Treitz;
this distal part is brought up as a ‘Roux-limb’. The excluded biliary
limb, including the gastric remnant, is connected to the bowel some
75–150 cm distal to the gastrojejunostomy (Fig. 2) [53]. The small
size of the upper gastric pouch is so reduced that it “restricts” or
limits the amount of food intake. It also provides satiety with smaller
portions of food. The lower gastric remnant no longer receives, stores,
and mixes food but remains secretory. The malabsorptive element
in gastric bypass is achieved as a result of the Roux-en-Y forma-
tion “bypassing” the upper part of the intestine. The length of the
Roux-en-Y limb was determined by the patient’s BMI; 100 cm for
those with a BMI of up to 48 kg/m2 and 150 cm for patients with a
higher BMI. This surgery can result in two-thirds of excess weight
loss within 2 years, albeit, with speciﬁc nutritional deﬁciencies re-
quiring replacement [8–10,53]. The complication rates are about 10%
in expert centres [10]. The main technical problem after gastric
bypass is anastomotic leakage, which in large series may reach 5%
[5]. It is a feared early complication appearing most commonly at
the gastrojejunostomy in RYGB with the incidence associated mor-
tality of 0.1% [53,58,59]. Higher BMI, male gender, re-operation, older
age and surgeon’s experience are associated with higher anasto-
motic leakage rates [60,61].
6.2. Omega loop mini gastric bypass (MGBP)
MGBP is being promoted as a quick and effective alternative to
the standard Roux-en-Y gastric bypass procedure. It works both by
restricting food intake at any one time, and by altering gut hor-
mones involved in appetite control. It seemsmore eﬃcient onweight
loss (70–80% at 2 years) and co-morbidities than the RYGBP, with
the advantage of being less technically diﬃcult and less morbid, es-
pecially for multi-complicated obese and/or the super obese. There
is immediate improvement of diabetes, with some patients coming
off insulin within a few days post-surgery [62]. It consists of a unique
gastro-jejunal anastomosis between a long gastric pouch (restric-
tive part) and a jejunal omega loop of 150–200 cm (malabsorptive
part) (Fig. 3). In effect, therefore, about 2m of small bowel has been
bypassed before absorption of food (and calories) can take place.
Fewer calories absorbed means weight loss. It is clear that in the
case of the MGBP there is only one anastomosis, whereas in
the RYGBP there are two – an upper and a lower. Because of this
the MGBP can be done in less time than the RYGBP and – at least
theoretically – with fewer early complications. However, this pro-
cedure could be at risk of biliary reﬂux and anastomotic ulcers with
dysplastic changes of the gastric and oesophageal mucosa. As a result,
MGBP remains a controversial subject, particularly as only one
monocentric randomized trial has compared it to the RYGBP, which
remains the gold standard [62].
6.3. Biliopancreatic diversion
Bilio-pancreatic diversion (BPD) is a combination of being ini-
tially restrictive but ultimatelymalabsorptive. Technically, BPD involves
a distal gastrectomy leaving a proximal stomach volume of 150–
400 ml. Depending on the BMI the ileum is divided 260–360 cm
proximal to the ileocecal valve, and the alimentary limb is con-
nected to the gastric pouch to create a Roux-en-Y gastroenterostomy.
An anastomosis is performed between the excluded biliopancreatic
limb and the alimentary limb 60 cm proximal to the terminal ileum
(Fig. 4). There is 1.1% 30 daymortality and a predicted 70–80%weight
loss at 2 years [11,63].
Bilio-pancreatic diversionwith duodenal switch (BPD-DS) ismildly
restrictive and mainly malabsorptive. It is technically a modiﬁca-
tion of the BDS incorporating a sleeve gastrectomy and a longer
common limb. In BPD-DS, a vertical sleeve gastrectomy (SG) is con-
structed and the duodenum is divided 4 cm distal to the pylorus.
The small bowel is divided at mid-point and the distal small bowel
(alimentary limb) is anastomosed to the duodenum. The ilio-
pancreatic limb (proximal small bowel) is anastomosed to the ileum
100 cm proximal to the terminal ileum (Fig. 5) [64]. There is a pre-
dicted 75–80% excess weight loss at 2 years especially as the excision
of the fundus in the sleeve gastrectomy would decrease circulat-
ing Ghrelin and reduce appetite [63]. However, the outcome of sleeve
gastrectomy when used primarily is the same as gastric bypass
[61,63]. In BPD-DS, leakage from the staple line is more common
than anastomotic leakage and the total enteric leakage rate is 5%
[65]. Dumping syndrome and anastomotic ulcers are less likely as
Fig. 2. Diagram of Roux-en-Y gastric bypass.
Fig. 3. Omega loop mini gastric bypass.
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compared to a BPD procedure because of the preservation of the
pylorus in BPD-DS [65].
6.4. Single anastomosis duodeno-ileostomy (SADI)
10–20% of patients have a sub-optimal result following bypass
or sleeve surgery. BPD-DS is quite a signiﬁcant malabsorptive pro-
cedure as there is usually only 1m of ‘common’ limb of small bowel.
The extra weight loss in BPD-DS is offset by a signiﬁcant risk of
protein or vitamin deﬁciency unless they are assiduous with their
diet, and a poorer quality of life from diarrhoea (6–8 times per day).
Single-anastomosis duodeno-ileal bypass with sleeve gastrec-
tomy is a simpliﬁcation of the duodenal switch that may behave
as a standard biliopancreatic diversion but easier and quicker to
perform. Given its effectiveness as a primary surgery it is hypoth-
esized that it would be successful as a second-step operation. The
anastomosis between the duodenum and the small bowel is central
to the procedure, and with a ‘common limb’ of small bowel mea-
suring 3 m long the increased bowel frequency is much less
compared to BPD-DS (Fig. 6a,b) [66]. Initial reports suggest that the
excess weight loss 5 years after SADI procedure remains compa-
rable to the DS at 90% (compared with 50–70% for the sleeve or
bypass) [67].
7. Complications
Patient education, thorough pre-operative work-up and regular
follow-up avoidmost complications of bariatric surgery. The surgery-
related complications are the usual complications of gastrointestinal
surgical procedures and are managed similarly. These include
haemorrhage, anastomotic leak, and anastomotic strictures [68–70].
The complications general to any abdominal operation include pneu-
monia, deep vein thrombosis, urinary retention and ileus. Small
bowel motility returns within a few hours and gastric and colonic
motility after a few days, depending on the degree of surgical trauma
[7–9].
7.1. Management of side-effects of bariatric surgery
The early unfavourable side effects of the bariatric gastric bypass
surgery are dehydration and constipation, and the dumping syn-
drome. Dehydration and constipation is a common problem and
patients must get used to drinking on a regular basis aiming for 1.5–
2 l/day. Re-education and occasional laxatives are advised. Almost
85 percent of patients who have gastric bypass (bariatric) surgery
will experience the ‘dumping syndrome’ but surgical revision is a
Fig. 4. Diagram of biliopancreatic diversion.
Fig. 5. Diagram of biliopancreatic diversion with duodenal switch.
Fig. 6. (a, b) Single anastomosis duodeno-ileal anastomosis (SADI) procedure.
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last resort [7–9]. Dumping syndrome requires re-education of patient
with avoidance of precipitating food stuffs. Highly restrictive gastric
pouch patients are advised to eat low volume meals frequently up
to 6 times a day and avoid a carbohydrate load which can lead to
dumping [71]. Although the parietal cell mass is small, stoma ul-
ceration remains a problem. Anastomotic ulcers are usually late
complications of bariatric surgery and occur in 2% of patients within
the ﬁrst post-operative year, and then in 0.5% for up to ﬁve years
[72]. They are common in smokers and patients who are H. pylori
positive. Such ulceration may respond to proton pump inhibition
but revisional surgerymay be required if the ulcer is resistant. Serum
gastrin levels may become excessive and the excluded stomachmay
require resection [60,61]. A ﬁstula between the pouch and the re-
maining stomach must be excluded [71].
Nutritional and vitamin deﬁciencies are late complications and
patient compliance is the major cause of such problems. BPD and
BPD-DS would initially require a post-operative diet high in protein
(60–80mg) [42,73]. Vitamin supplementation on a daily basis is es-
sential and a B12 injection at maintenance dose usually suﬃces [73].
Internal herniasmay easily develop after laparoscopic gastric bypass
in which small mesenteric defects (transverse mesocolon, entero-
enterostomy or behind the Roux limb) can be created and there are
fewer adhesions to tether small bowel loops and prevent them from
herniating [74]. In addition patients who have greater degree of
weight loss after laparoscopic Roux-en-Y gastric bypass may bemore
prone to internal hernia because of loss of the protective space-
occupying effect of mesenteric fat [75]. The reported frequency ranges
from 0.4% to 5.5% in RYGB [76]. Long-term data over seven years
record a hernia rate of 38% in BPD/BPD-DS [77]. High index of sus-
picion is required in all patients with abdominal painwith or without
small bowel obstruction. Delayed diagnosis may lead to life-
threatening complications of strangulation in the early or late post-
operative period [76,77]. Although the laparoscopic approach may
result in higher rates, closure of potential defects at time of primary
surgery is not, however, universal. Standardization of the proce-
dures and new surgical techniques where the mesentery windows
are surgically closed may reduce the rate to as low as 1% [77].
Incisional hernias can occur but are less common with the in-
creased use of laparoscopic techniques [58,59]. The risk of additional
surgery for symptomatic gallstones from the inadvertent va-
gotomy is prevented by a prophylactic cholecystectomy during the
bariatric gastric bypass procedures [7–11]. Hypersideroblastosis is
an uncommon problem due to hyperplasia of the B cells of the pan-
creas as a result of excessive weight loss giving rise to chronic
hypoglycaemia. Pancreatic resection may be required [71].
8. Revision gastric bypass (bariatric) surgery
As the number of primary bariatric procedures increases so does
the rate of re-operations as a consequence of either a failed primary
procedure or complication. It is important to evaluate whether the
cause is a technical failure or due to poor patient compliance. Dis-
cussion at the bariatric MDT is important in managing such patients
with re-referral to both dietetics and psychology. Redo bariatric
surgery is associated with a higher mortality (2%) and morbidity
(13% leak rate) compared with the primary operation [71]. Ana-
tomical assessment includes plain radiography, contrast swallows,
and contrast follow-through studies for a ‘road map’ of the surgi-
cally altered anatomy of the upper GI tract. Endoscopy is a useful
adjunct in looking at anastomotic strictures, ulcers and assessing
pouch sizes. Blood tests are needed for a full haematological and
biochemical proﬁle including trace elements and vitamin D. The
revisional surgical approaches may include reversal of the obso-
lete jejunal–ileal bypass (high incidence of malabsorption), reversal/
revision of Roux-en-Y gastric bypass and BPD/switch for
malabsorption, removal of eroded pre-anastomotic rings in
Roux-en-Y bypass pouches (e.g. Fobi ring) and revision of gastric
pouches, gastrojejunostomies, jejunal-jejunostomies, remnant gas-
trectomies for enlargements, strictures, and gastrogastric ﬁstulae,
respectively [53,78,79]. These revision procedures carry with them
Table 1
Summary of gastric bypass procedures.





Billroth II gastrectomy Non- primary bariatric
(restrictive)









Gastric pouch (15–30 ml)
100 cm jejunum (BMI <48 kg/
m2)
150 cm jejunum (BMI >48 kg/
m2)
60–80% at 2 yrs 0.1 Dehydration and constipation,
dumping syndrome,
anastomotic ulcers, nutrition
and vitamin (B12, D)
deﬁciencies, internal hernias




Long gastric pouch (restrictive
part), jejunal omega loop of
150–200 cm (malabsorptive
part)






Gastric pouch (150–400 ml)
Absorptive ‘common’ limb
(60 cm proximal to terminal
ileum)















(100 cm proximal to terminal
ileum)












‘common’ limb 3 m
75–80% at 2 yrs, 90% at 5 yrs Less diarrhoea than BPD-DS,
protein deﬁciency
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a higher risk of complication than the original procedure, revi-
sions must be performed by experienced surgeons.
9. Outcome of bariatric surgery
Metabolic (bariatric) surgery results in better glucose control than
medical therapy and overwhelmingly leads to disease remission
[7–10]. Results at 2 years showed DM remission of 0% in a medical
cohort, 75% in the gastric bypass group and 95% for the
biliopancreatic diversion group [78]. Operative intervention is more
effective than conservative measures at present in treatment of
obesity, resolution of co-morbidities and cost effectiveness. At 1 year
the mean total % weight loss from all surgical approaches is 20–
21.6% and 1.4–5.5% from non-surgical approaches. At 2 years there
is 16–28% weight loss following surgery but weight gain of 0.1–
0.5% with non-surgical approaches [80]. For people with very high
BMI, BPD-DS resulted in greater weight loss with sustainability than
RYGB (Table 1) [9]. The Swedish obesity study demonstrated main-
tenance of weight loss at 10 years following surgery with weight
gain in the non-surgical arm. A 40% reduction of death over a 7 year
period and a decrease in ischaemic heart disease of 56% were re-
ported. There were no differences in weight loss between the open
and the laparoscopic approach [81]. Across all studies adverse event
and reoperation rates were generally poorly reported. Most trials
followed participants for only one or two years, and therefore the
long-term effects of surgery may remain unclear [82]. However, the
assessment of outcome is not simply based on clinical effective-
ness but also on the cost effectiveness which includes savings from
correction of hypertension, improved cardiac status, resolution or
amelioration of diabetesmellitus and respiratory function and gainful
employment [83,84].
10. Conclusions
Theweight-related side-effect of gastric bypass surgery for benign
or malignant disease has inadvertently pioneered primary meta-
bolic (bariatric) surgery. Because metabolic (bariatric) surgery may
have serious side effects and complications, the long-term health
beneﬁts must be considered and found greater than the risks for
the individual patient. Post gastrectomy side effects are few after
Roux-en-Y gastric bypass but more are seen after Billroth II bypass
procedures thus requiring conversion to a Roux-en-Y. Bile reﬂux gas-
tritis and gastroparesis are the most common post gastrectomy
complications. Close multidisciplinary follow-upwith surgeons, spe-
cialist nurse, and dieticians is crucial following gastric bypass surgery
to optimize both physical and psychological quality of life.
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